GAPDH and Parkinson disease: In a therapeutic context, selegiline—a pharmacological agent employed in Parkinson's disease treatment—can inhibit the S‐nitrosylation of GAPDH, thereby precluding its interaction with Siah1 and constraining the nuclear translocation of the GAPDH‐Siah complex, thus limiting cellular apoptosis.158, 165, 166